Agilent Technologies ($A) reported earnings on May 27, 2026. The headline numbers tell a split story: revenue grew 7.0% year over year, but earnings per share fell 3.6% over the same period.
At a current price of $115.27 and a market cap of $32.52B, the stock trades at a trailing P/E of 25.4. The forward P/E drops to 17.6, which suggests the market expects earnings to recover from the current dip. The dividend yield sits at 0.9%.
The ACCE score for $A is 48 out of 100, placing it in neutral territory. The average analyst price target is $160.63, a significant gap above the current price.
Get the ACCE weekly digest
Index returns, picks recap, score movers - every Sunday. No fluff.
We do not have guidance commentary from this earnings report, so forward projections from management are not available at this time.
What it means
The 7% revenue gain shows Agilent is still moving product and growing its top line. That matters in a healthcare instrumentation and life sciences tools business where demand cycles can be long and lumpy. The company has been navigating a post-pandemic inventory correction across its biopharma customer base, and a return to positive revenue growth is a concrete step in the right direction.
The EPS decline of 3.6% is the friction point. Revenue growing while earnings shrink points to margin pressure — whether from higher input costs, increased operating expenses, or a less favorable product mix. Without guidance commentary, it is hard to know whether management sees this as a temporary squeeze or a structural shift.
The gap between the trailing P/E of 25.4 and the forward P/E of 17.6 is notable. That compression only makes sense if earnings are expected to grow meaningfully in the coming year. If that recovery does not materialize, the current valuation looks stretched relative to where earnings actually are today.
The analyst consensus target of $160.63 against a current price of $115.27 implies roughly 39% upside according to the Street. That is a wide gap, and it likely reflects expectations that the earnings recovery embedded in the forward P/E does play out.
For now, the ACCE score of 48 reflects the mixed picture: a business growing revenue but not yet translating that growth into earnings. Watch for margin commentary and any updated guidance in follow-on investor communications.
See the current price and updated score at acceinvestments.com/stocks/A.
See the full picture, free
ACCE scores thousands of stocks across six valuation models, with fair value, conviction and the full thesis on every name. Start free, no card required.
